WallStSmart

Medtronic PLC (MDT)vsInspireMD Inc (NSPR)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Medtronic PLC generates 327002% more annual revenue ($35.48B vs $10.85M). MDT leads profitability with a 13.0% profit margin vs 0.0%. MDT earns a higher WallStSmart Score of 61/100 (C+).

MDT

Buy

61

out of 100

Grade: C+

Growth: 4.7Profit: 6.5Value: 6.0Quality: 4.8
Piotroski: 2/9

NSPR

Hold

41

out of 100

Grade: D

Growth: 8.0Profit: 2.5Value: 6.7Quality: 6.5
Piotroski: 3/9Altman Z: -5.09
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

MDTUndervalued (+10.3%)

Margin of Safety

+10.3%

Fair Value

$89.60

Current Price

$81.67

$7.93 discount

UndervaluedFair: $89.60Overvalued
NSPRUndervalued (+47.1%)

Margin of Safety

+47.1%

Fair Value

$3.26

Current Price

$0.93

$2.33 discount

UndervaluedFair: $3.26Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

MDT4 strengths · Avg: 8.3/10
Market CapQuality
$94.69B9/10

Large-cap with strong market position

Price/BookValuation
2.1x8/10

Reasonable price relative to book value

Operating MarginProfitability
20.0%8/10

Strong operational efficiency at 20.0%

Free Cash FlowQuality
$2.08B8/10

Generating 2.1B in free cash flow

NSPR3 strengths · Avg: 10.0/10
Price/BookValuation
1.0x10/10

Reasonable price relative to book value

Revenue GrowthGrowth
122.2%10/10

Revenue surging 122.2% year-over-year

Debt/EquityHealth
0.0510/10

Conservative balance sheet, low leverage

Areas to Watch

MDT2 concerns · Avg: 2.5/10
Piotroski F-ScoreQuality
2/93/10

Weak financial health signals

EPS GrowthGrowth
-11.8%2/10

Earnings declined 11.8%

NSPR4 concerns · Avg: 3.3/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$35.85M3/10

Smaller company, higher risk/reward

Profit MarginProfitability
0.0%3/10

0.0% margin — thin

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

Comparative Analysis Report

WallStSmart Research

Bull Case : MDT

The strongest argument for MDT centers on Market Cap, Price/Book, Operating Margin. PEG of 1.29 suggests the stock is reasonably priced for its growth.

Bull Case : NSPR

The strongest argument for NSPR centers on Price/Book, Revenue Growth, Debt/Equity. Revenue growth of 122.2% demonstrates continued momentum.

Bear Case : MDT

The primary concerns for MDT are Piotroski F-Score, EPS Growth.

Bear Case : NSPR

The primary concerns for NSPR are EPS Growth, Market Cap, Profit Margin.

Key Dynamics to Monitor

MDT profiles as a value stock while NSPR is a hypergrowth play — different risk/reward profiles.

NSPR carries more volatility with a beta of 0.74 — expect wider price swings.

NSPR is growing revenue faster at 122.2% — sustainability is the question.

MDT generates stronger free cash flow (2.1B), providing more financial flexibility.

Bottom Line

MDT scores higher overall (61/100 vs 41/100). NSPR offers better value entry with a 47.1% margin of safety. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Medtronic PLC

HEALTHCARE · MEDICAL DEVICES · USA

Medtronic plc is an American-Irish registered medical device company that primarily operates in the United States. Medtronic has an operational and executive headquarters in Fridley, Minnesota in the US.

InspireMD Inc

HEALTHCARE · MEDICAL DEVICES · USA

InspireMD, Inc., a medical device company, is focused on the development and commercialization of proprietary MicroNet stent platform technology for the treatment of coronary and vascular disease in Europe, Latin America, the Middle East, and Asia. The company is headquartered in Tel Aviv, Israel.

Want to dig deeper into these stocks?